Lab21 gains new platform for developing molecular Dx faster
This article was originally published in Clinica
Executive Summary
UK personalised medicine specialist Lab21 has struck a worldwide licensing deal with Cooperative Diagnostics, giving it exclusive access to real-time PCR technology that should allow it to fast-track the development of its molecular diagnostics pipeline. Lab21 is initially focusing on the oncology and infectious disease areas, and hopes to launch the first of its CE-marked companion diagnostics using the technology during the first half of this year.